A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.

Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis Russell Zelig Szmulewitz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.

Keyphrases

prostate cancer
end stage renal disease
study protocol
phase iii
clinical trial
ejection fraction
newly diagnosed
phase ii
peritoneal dialysis
prognostic factors
randomized controlled trial
radical prostatectomy
patient reported
anti inflammatory drugs